It is largely unclear how MDSCs contribute to the development of primary Sjögren's syndrome (pSS). In experimental SS (ESS) mice, MDSCs were significantly increased but exhibited gradually diminished suppressive capacity during the disease progression. The ligand for glucocorticoid-induced TNFR family-related protein (GITRL) was increased with the development of pSS, and the increased GITRL was found to down-regulate the function of MDSCs while blocking GITR signal in MDSCs significantly restored their function and ameliorated ESS progression in mice. In pSS patients, expanded MDSCs expressed lower level of arginase were observed in patients with higher SSDAI. Moreover, the increased GITRL in serum was also found to closely correlate with the aberrant function of MDSCs. Together, our studies have demonstrated a critical role of GITRL in modulating the suppressive capacity of MDSCs in pSS, which may facilitate the validation of GITRL as a therapeutic target for the treatment of pSS.
Introduction
Primary Sjögren's syndrome (pSS), a systemic autoimmune disease, is characterized by lymphocytic infiltration of the exocrine glands, primarily salivary and lachrymal glands, leading to the loss of secretary function (Fox, 2005; Nocturne & Mariette, 2013) . Although the etiology of pSS remains largely unclear, many studies have demonstrated the involvement of dendritic cells (DCs), NK cells, B cells and T cells in the pathogenesis of SS (Adamson et al, 1983; Cornec et al, 2012; Nocturne & Mariette, 2013; Singh & Cohen, 2012) . Recent studies have found that Th1 and Th17 immune responses play a critical role in the development of pSS (Kolkowski et al, 1999; Lin et al, 2015; Mitsias et al, 2002; Nguyen et al, 2008; Sakai et al, 2008; Xiao et al, 2017) .
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells with immunosuppressive functions ). Murine MDSCs are characterized by co-expression of CD11b and Gr-1, which can be further subdivided into CD11b + Ly-6G -Ly-6C high monocytic MDSCs (M-MDSCs) and CD11b + Ly-6G + Ly-6C low polymorphonuclear MDSCs (PMN-MDSCs). Human MDSCs are CD11b + CD33 + HLA-DR − cells. MDSCs have been shown to promote tumor progression by suppressing T cell-mediated anti-tumor immunity in cancer Rabinovich et al, 2007) . Recently, MDSCs are shown to be involved in the pathogenesis of various autoimmune disorders, including type 1 diabetes, multiple sclerosis (MS), rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), but the role of MDSCs in the development of 4 pSS has remained poorly understood.
Glucocorticoid-induced tumor necrosis factor receptor (TNFR) family-related protein (GITR) is a type I transmembrane protein of TNF superfamily, which is highly expressed on Tregs, but low levels on conventional effector T cells and is rapidly up-regulated after activation (Kanamaru et al, 2004) . The ligand for GITR (GITRL) is a type II transmembrane protein predominantly expressed on endothelial cells, dendritic cells (DCs), macrophages and B cells (Kim et al, 2003; Tone et al, 2003) .
The interaction of GITR and GITRL has been demonstrated to modulate both innate and adaptive immune responses (Azuma, 2010) . The engagement of GITR on effector T cells exhibits a positive co-stimulatory signal leading to T cell proliferation and cytokine production (Chattopadhyay et al, 2008) . However, GITR stimulation on regulatory T cells has been suggested to abolish the suppressive capacity of the cells (Chattopadhyay et al, 2007; Shevach & Stephens, 2006) . Previous studies including our recent findings have revealed that GITR/GITRL pathway is involved in the pathogenesis of autoimmune diseases, including RA (Cuzzocrea et al, 2005; , MS (Kohm et al, 2004) and autoimmune diabetes (You et al, 2009) .
Recently, GITRL is reported to be closely associated with the disease severity in pSS patients and MRL-Fas lpr mice (Gan et al, 2013; Saito et al, 2013) . However, the underlying mechanism for GITRL in regulating the progression in pSS has been largely unclear.
In this study, we characterized the kinetic change and functional alteration of MDSCs in experimental SS (ESS) mice and pSS patients and identified a critical role 5 of GITRL in regulating the suppressive function of MDSCs in the pathogenesis of pSS.
Results

Expanded MDSCs during ESS development in mice
In ESS mice, the kinetic change of CD11b + Gr-1 + MDSCs was analyzed in the spleen, CLN and peripheral blood during the progression of the disease. Compared to the naïve mice (day 0) or control mice immunized with adjuvant alone, percentages of MDSCs in different samples remarkably increased and reached a peak around day 14 or 35 post immunization ( Figure 1A -C). Flow cytometric analysis identified a population of MDSCs infiltrated in SG 10 weeks after immunization ( Figure 1D ), which was further confirmed by immunofluorescence microscopy ( Figure 1E ).
Similarly, both the number and the proportion of two subsets, CD11b + Ly-6G -Ly-6C high M-MDSCs and CD11b + Ly-6G + Ly-6C low PMN-MDSCs were also increased during the course of ESS ( Figure 1F , G). Of note, mice treated with adjuvant showed only a slight increase of MDSCs at the early stage.
MDSCs gradually lose their suppressive capacity during ESS progression
We next defined the maturation and function of the increased MDSCs, the expression of CD40, CD80, CD86 and MHCII on MDSCs and their suppressive capacity on T cell proliferation were analyzed. As shown in Figure 2A , MDSCs (M-MDSCs/PMN-MDSCs) isolated from the early stage of ESS (day 18) expressed low levels of CD40, CD80, CD86 and MHCⅡ, which displayed an immature and 6 undifferentiated phenotype. However, expression of these molecules was gradually up-regulated with the development of the disease, and MDSCs from the late stage of ESS (10 weeks) expressed high levels of these surface markers, which exhibited a more mature status. Co-culture of MDSCs (M-MDSCs/PMN-MDSCs) and T cells indicated the early-stage MDSCs displayed highly efficient activity in suppressing the T cell proliferation while the late-stage cells almost lost their suppressive capacity ( Figure 2B) . Similarly, the suppressive factors secreted by MDSCs, including arginase and NO, were also down-regulated with the development of ESS ( Figure 2C ).
Furthermore, MDSCs infiltrated in SG produced less arginase when compared to the early-stage MDSCs in spleens, which indicates that MDSCs migrated into the local inflammatory sites are of weak suppressivity ( Figure 2D ). Together, these results suggest that the suppressive capacity of MDSCs was down-regulated during the progression of ESS.
Next, we further observed the suppressivity of MDSCs in vivo. Early-stage or late-stage MDSCs were adoptively transferred to ESS mice on days 18 and 25 ( Figure   EV1A ). Remarkably, the early-stage MDSCs, which possessed strong suppressive capacity, significantly reversed the saliva flow rate to normal level while the late-stage cells did not ( Figure EV1B ). Furthermore, levels of autoantibodies against total SG antigens, ANA and anti-M3R antibodies were also decreased after early-stage MDSCs treatment ( Figure EV1C ). Notably, the early-stage MDSCs treated group displayed a smaller CLN and SG when compared to the control group ( Figure EV1D ).
Histological examination further identified the pathological changes in local 7 submandibular glands. Only little lymphocyte infiltration was observed in SG after early-aged MDSCs treatment. In contrast, the late-aged MDSCs treatment did not display any therapeutic effect, and even remarkably aggravated the tissue destruction,
showing multiple lymphocytic foci in SG ( Figure EV1E ). Additionally, Th1 and Th17 responses were also reduced after the treatment of early-stage MDSCs while the late-stage MDSCs did not ( Figure EV1 F, G). Similar results were also observed in the serum levels of IFN-γ and IL-17 ( Figure EV1H ). Taken together, these findings reveal that early-stage MDSCs could ameliorate the progression of ESS and reduce the Th1/Th17 responses while late-stage MDSCs could not.
GITRL impairs the function of MDSCs and enhances the progression of ESS
The above in vitro and in vivo experiments have clarified the reduction of the suppressive function of MDSCs during the development of ESS, we next investigated the potential factors responsible for the altered function of MDSCs. We firstly found that GITR was expressed on total MDSCs and two subpopulations ( Figure 3A) .
Moreover, the level of GITR was up-regulated with the disease progression ( Figure   3B ). Notably, GITRL was also gradually increased in the spleen, CLN and SG with the progression of the disease ( Figure 3C ). To further ascertain the contributed cell population, we analyzed three populations which mainly expressed GITRL in peripheral immune organs. As shown in Figure 3D and 3E, GITRL expressed on both macrophages and B cells was increased in ESS mice. Thus, these results suggest that
MDSCs in ESS mice might be regulated by the increased GITRL in vivo.
To investigate whether the function of MDSCs would be regulated by the increased GITRL, recombinant GITRL was used to stimulate the early-stage MDSCs isolated from ESS mice. After GITRL treatment, levels of CD40, CD80, CD86 and MHCⅡ on total MDSCs, M-MDSCs and PMN-MDSCs were enhanced ( Figure 3F ), and the suppressive function of MDSCs (M-MDSCs and PMN-MDSCs) on CD4 + T cells was decreased ( Figure 3G ). Similarly, reduced arginase and NO was observed after GITRL stimulation ( Figure 3H ). All these results suggest GITRL could promote the maturation of MDSCs and down-regulate the suppressive capability of the cells.
We next investigated the effect of GITRL-treated MDSCs in inhibiting the ESS development. Early-stage MDSCs treated with or without GITRL were adoptively transferred to ESS mice on days 18 and 25 respectively ( Figure EV2A ). When compared to the Ctrl-MDSC group, saliva flow rate was significantly decreased and the levels of autoantibodies were enhanced after transferring with GITRL-treated MDSCs ( Figure EV2B -E). In addition, GITRL-MDSCs treatment showed a bigger CLN and SG, and more lymphocytes were detected in local submandibular glands ( Figure EV2F , G). Furthermore, GITRL-MDSCs treatment did not reduce the Th1 and Th17 responses while the Ctrl-MDSCs significantly inhibit the immune responses ( Figure EV2H -J). Together, these findings suggest that GITRL treatment make the early-stage MDSCs lose their primary capability in inhibiting the ESS development.
GITRL treatment attenuates the suppressive effect of MDSCs in ESS mice
Exogenous GITRL was administrated into the ESS mice starting from day 18 for three times (Figure 4 
Increased GITRL correlates with impaired function of MDSCs in pSS patients
Flow cytometric analysis was performed to examine the frequencies of CD11b + CD33 + HLA-DR -MDSCs in peripheral blood from pSS patients and healthy controls. Compared to healthy controls, the percentage of MDSCs was significantly increased in patients with pSS ( Figure 6A) . A further analysis showed these accumulated MDSCs in pSS patients secreted low level of arginase ( Figure 6B ), and the level of arginase was negatively correlated with the disease activity ( Figure 6C ).
In Figure 6J) , and the arginase level in MDSCs was also reduced ( Figure 6K ). All these data suggest that the suppressive function of MDSCs in pSS patients is closely related to the severity of the disease, which is probably regulated by 11 GITR/GITRL pathway.
Discussion
Due to the suppressive capability of MDSCs, accumulating investigations have devoted to exploit their potential in the treatment of autoimmune diseases (Fujii et al, 2013; Ioannou et al, 2012; Jeong et al, 2018; Li et al, 2014; Zhu et al, 2007) .
However, in this study, we showed that frequencies of MDSCs and their subsets were enhanced, but they gradually lost their suppressive function with the development of ESS, thus leading to the uncontrollable expansion of Th1 and Th17 immune responses.
Further investigation demonstrated that it was the enhanced GITRL that modulate the suppressivity of MDSCs directly through GITR/GITRL pathway. Taken together, our findings have revealed that the increased GITRL could promote the maturation of MDSCs, and down-regulated the suppressive capacity of the cells, which further promoted the progression of pSS.
To date, there was no evidence showing the relationship between MDSCs and pSS. However, the role of MDSCs in other autoimmune diseases has been discussed for years. The expansion of MDSCs was found in the majority of the autoimmune diseases, such as MS, RA, type I diabetes, autoimmune uveoretinitis and SLE (Fujii et al, 2013; Guo et al, 2016; Ioannou et al, 2012; Jeong et al, 2018; Yi et al, 2012; Yin et al, 2010; Zhu et al, 2007) . Nevertheless, the conclusions about the role of MDSCs in different autoimmune diseases were not totally identical, and even in the same disease, The conflicting results on the role of MDSCs in preventing autoimmune diseases are mainly due to the high heterogeneity and plasticity of myeloid cells whose phenotypes and functions are largely dependent on local microenvironments (Cripps & Gorham, 2011; Melero-Jerez et al, 2016; Sunderkotter et al, 2004; Youn & Gabrilovich, 2010) . In this study, we found that GITR was expressed on MDSCs for the first time, both in ESS mice and pSS patients, and the expression of GITR on MDSCs was significantly enhanced with the 14 progression of the disease. Besides, GITRL was also significantly increased in ESS mice and patients. Actually, Gan et al. have reported the increased GITRL was closely associated with the severity of the disease in pSS patients (Gan et al, 2013) , which was consistent with our results. Further investigation revealed that the increased GITRL was mainly ascribed to macrophages and B cells. Thus, the next question is whether MDSCs with suppressive function will be regulated by the increased GITRL. 
Materials and Methods
Mice
Female C57BL/6 mice at 8-week-old were purchased from Experimental Animal 
Induction of ESS model
The ESS mouse model was induced as previously described (Lin et al, 2015) . Briefly, bilateral salivary glands were isolated from female C57BL/6 mice for homogenization in PBS to prepare salivary glands (SG) proteins. Naïve mice were immunized with SG proteins emulsified in an equal volume of CFA (Sigma-Aldrich) to a concentration of 2 mg/mL (100µl each mouse) s.c. on the neck on days 0 and 7. On day 14, the booster injection was performed with a dose of 1 mg/mL SG proteins emulsified in Freund's incomplete adjuvant (Sigma-Aldrich). Naïve mice immunized with adjuvant alone 16 served as adjuvant controls.
Detection of saliva flow rate
Saliva flow rates were measured as previously described (Lin et al, 2015) . In brief, mice were anesthetized and injected intraperitoneally with pilocarpine (Sigma-Aldrich) at a dose of 5 mg/kg body weight. Saliva was then collected using a 20-μl pipet tip from the oral cavity for 15min. 
Flow cytometric analysis
MDSC isolation and suppression assay
CD11b + Gr-1 + MDSCs were isolated from the spleens of ESS mice using a FACSAria II SORP (Becton Dickinson) cell sorter. M-MDSCs and PMN-MDSCs were isolated using a mouse MDSC isolation kit (Miltenyi Biotec) following the manufacturer's protocol. MDSC suppression assay was performed as we previously described .
Quantitative real-time PCR (qRT-PCR)
The quantitative real-time PCR were performed as previously described (Tian et al, 2011) . The sequences for the primers used are: mGITR, Forward -5'-CTCAGGAGAAGCACTATGGG' -3' , Reverse-5'-AGCTGGGCAAGTCTTGTAG'
Reverse-5'-TAAAACGCAGCTCAGTAACAGTCCG-3'. β-actin was used as an internal control.
Enzyme-linked immunosorbent assay
Autoantibodies against SG proteins, ANA (Elabscience), anti-M3 muscarinic receptor (M3R) antibodies, IFN-γ and IL-17 (eBioscience) in the serum of ESS mice and human GITRL in serum (R&D system) was assessed by ELISA.
Detection of arginase activity and NO production
The activity of arginase and NO concentration were measured as previously described (Tian et al, 2013) .
Transfection
GITR siRNA, and negative controls were synthesized by RiboBio. Oligonucleotide transfection was performed with Entranster-R (Engreen Biosystem) according to the manufacturer's instructions.
Histological assessment and immunofluorescence microscopy
SG tissues were paraffin embedded, sectioned and stained with H&E. For immunofluorescence microscopy, frozen sections were incubated with FITC-conjugated anti-CD11b mAb (eBioscience) and PE-conjugated anti-CD33 mAb (eBioscience). Hoechst 33342 (Beyotime) was used to label nuclei. Matched isotype controls (eBioscience) were used for control staining.
Patient samples
Whole blood samples were collected from patients with pSS (n=25) and healthy controls (n=25). All patients were diagnosed with active according to the SS Disease Activity Index (SSDAI) scores. The study protocols and consent forms were approved by the Institutional Medical Ethics Review Board of Jiangsu University.
Generation of human MDSCs
Peripheral blood mononuclear cells (PBMC) were isolated from healthy volunteer donors by density gradient centrifugation using Ficoll-Hypaque solution (TBD sciences). PBMC were cultured with GM-CSF (10ng/ml, PeproTech) and IL-6 (10ng/ml, PeproTech) for 7 days, and the cytokines were refreshed every 2-3 days.
After 1 week, all cells were collected and adherent cells were removed using nonprotease cell detachment solution Detachin (Genlantis). CD33 + cells were isolated using anti-CD33 magnetic microbeads (Miltenyi Biotec). The purity of isolated cells was >90%.
T-cell suppression assay
Human CD4 + T cells were isolated from healthy volunteer donors using anti-CD4 microbeads (Miltenyi Biotec). CD4 + T cells were labeled with CFSE (5µM, Invitrogen) and co-cultured with human CD33 + cells at a ratio of 2:1 in 96-well plates (Costar) in the presence of anti-CD3 (eBioscience) and anti-CD28 (eBioscience) mAbs for 3 days. CFSE fluorescence intensity was analyzed to determine the proliferation of CD4 + T cells by flow cytometry.
Statistical analysis
The statistical significance was determined by the Student's t test or one-way ANOVA. 
